Literature DB >> 11675036

Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies.

Y Liu1, L Belayev, W Zhao, R Busto, A Belayev, M D Ginsberg.   

Abstract

In recent experimental studies, we demonstrated a highly beneficial neuroprotective effect of moderate- to high-dose human albumin treatment of transient focal cerebral ischemia, but we did not define the effect of albumin therapy in permanent focal cerebral ischemia. In this study, anesthetized Sprague-Dawley rats were subjected to permanent middle cerebral artery occlusion by retrograde insertion of an intraluminal nylon suture coated with poly-L-lysine. Albumin was administered i.v. at 2 h after onset of middle cerebral artery occlusion, in doses of either 1.25 (n=8) or 2.5 g/kg (n=6). In a separate group of animals, albumin (2.5 g/kg) was given 1 h after middle cerebral artery occlusion (n=6). Vehicle-treated rats (n=6) received 0.9% saline in equivalent volumes. Neurological status was evaluated during and 24 h after middle cerebral artery occlusion. One day after middle cerebral artery occlusion, infarct volumes and brain edema were determined. In a separate group of animals, cortical perfusion was assessed by Laser-Doppler perfusion imaging. Albumin (1.25 g/kg; n=3) or vehicle (sodium chloride 0.9%; n=3) was administered at 2 h after onset of middle cerebral artery occlusion. Higher-dose albumin therapy (2.5 g/kg) significantly improved the neurological score compared to vehicle rats at 24 h, when administered at either 1 or 2 h after middle cerebral artery occlusion. Total infarct volume was reduced by albumin (2.5 g/kg given at 2 h) by 32% compared with vehicle-treated rats. Both albumin doses (1.25 and 2.5 g/kg) significantly reduced cortical and striatal infarct areas at several coronal levels when administered at 2 h after middle cerebral artery occlusion. Brain swelling was not affected by albumin treatment. Cortical perfusion declined during middle cerebral artery occlusion in both groups. Treatment with albumin led to 48% increases in cortical perfusion (P<0.002), but saline caused no change. These results support a beneficial effect of albumin therapy in permanent focal cerebral ischemia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11675036     DOI: 10.1016/s0014-2999(01)01255-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  27 in total

1.  Treatment of subarachnoid hemorrhage with human albumin: ALISAH study. Rationale and design.

Authors:  Jose I Suarez; Renee H Martin
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

Review 2.  Neuroprotective agents for the treatment of acute ischemic stroke.

Authors:  Bruce Ovbiagele; Chelsea S Kidwell; Sidney Starkman; Jeffrey L Saver
Journal:  Curr Neurol Neurosci Rep       Date:  2003-01       Impact factor: 5.081

3.  Polynitroxyl albumin and albumin therapy after pediatric asphyxial cardiac arrest: effects on cerebral blood flow and neurologic outcome.

Authors:  Mioara D Manole; Patrick M Kochanek; Lesley M Foley; T Kevin Hitchens; Hülya Bayır; Henry Alexander; Robert Garman; Li Ma; Carleton J C Hsia; Chien Ho; Robert S B Clark
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-30       Impact factor: 6.200

Review 4.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

Review 5.  Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials.

Authors:  Jialing Liu; Yongting Wang; Yosuke Akamatsu; Chih Cheng Lee; R Anne Stetler; Michael T Lawton; Guo-Yuan Yang
Journal:  Prog Neurobiol       Date:  2013-11-27       Impact factor: 11.685

6.  Neuroprotective Effects of Pregabalin on Cerebral Ischemia and Reperfusion.

Authors:  Sanem Aşcı; Serpil Demirci; Halil Aşcı; Duygu Kumbul Doğuç; İbrahim Onaran
Journal:  Balkan Med J       Date:  2016-03-01       Impact factor: 2.021

Review 7.  Investigational therapies for ischemic stroke: neuroprotection and neurorecovery.

Authors:  Preeti Sahota; Sean I Savitz
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

8.  Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death.

Authors:  Thiruma V Arumugam; Sung-Chun Tang; Justin D Lathia; Aiwu Cheng; Mohamed R Mughal; Srinivasulu Chigurupati; Tim Magnus; Sic L Chan; Dong-Gyu Jo; Xin Ouyang; David P Fairlie; Daniel N Granger; Alexander Vortmeyer; Milan Basta; Mark P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-21       Impact factor: 11.205

9.  Albumin-Induced Neuroprotection in Focal Cerebral Ischemia in the ALIAS Trial: Does Severity, Mechanism, and Time of Infusion Matter?

Authors:  Rakesh Khatri; Mohammad Rauf Afzal; Gustavo J Rodriguez; Alberto Maud; Muhammad Shah Miran; Mohtashim Arbaab Qureshi; Salvador Cruz-Flores; Adnan I Qureshi
Journal:  Neurocrit Care       Date:  2018-02       Impact factor: 3.210

10.  Albumin therapy improves local vascular dynamics in a rat model of primary microvascular thrombosis: a two-photon laser-scanning microscopy study.

Authors:  Anitha Nimmagadda; Hee-Pyoung Park; Ricardo Prado; Myron D Ginsberg
Journal:  Stroke       Date:  2007-11-21       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.